Idera to Release 2019 Second Quarter Results on August 8, 2019
The company will host a conference call and live audio webcast at
To participate in the conference call, please dial (844) 882-7837 (domestic) and (574) 990-9824 (international). The webcast can be accessed live or in archived form in the “Investors” section of the company’s website at www.iderapharma.com. Archived versions will also be available on the Company’s website after the event for 90 days.
About Idera Pharmaceuticals
Harnessing the approach of the earliest researchers in immunotherapy and the company’s vast experience in developing proprietary immunomodulatory platforms, Idera’s TLR agonist development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy.
Idera Pharmaceuticals Contact
SVP, Investor Relations & Corporate Communications
Phone: 484-348-1677
rdoody@iderapharma.com
Source: Idera Pharmaceuticals, Inc.